News | Stem Cell Therapies | September 04, 2015

No Benefit to Gene Transfer Therapy for Heart Failure Patients

Patients saw no reduction in recurrent events in largest gene therapy study to date for the population

CUPID 2, gene transfer therapy, heart failure patients, no benefit, ESC 2015, SERCA2a

September 4, 2015 — Gene transfer therapy to correct an enzyme abnormality involved in myocardial contraction and relaxation did not improve outcomes in heart failure patients with reduced ejection fraction, results of the CUPID 2 study show.

The findings, presented at the European Society of Cardiology (ESC) Congress 2015, represent the largest gene transfer study to date in this population.

“Despite promising results from earlier studies, the therapy did not reduce either recurrent heart failure events or terminal events in the overall study population or in pre-specified subgroups,” said principal investigator Barry Greenberg, M.D., from the University of California San Diego (UCSD) Sulpizio Cardiovascular Center.

But the results provide some important information for future research in this area, he said.

“They demonstrate that clinical trials testing gene transfer can be carried out effectively in heart failure patients, and that using intracoronary delivery of an adeno-associated virus (AAV) vector at this dose is safe,” he said.

CUPID 2 was based on the observation that deficiency of the enzyme sarcoplasmic reticulum CA2+ ATPase (SERCA2a), is linked to progression of heart failure and correction of this abnormality by gene transfer may improve cardiac function.

A pilot study by the same group showed that a single intracoronary infusion of the SERCA2a gene using an AAV vector had favorable effects in patients with advanced heart failure (Circulation 2011;124:304–13).

CUPID 2 (Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease Phase 2b) investigated this finding further, enrolling 250 heart failure patients with reduced ejection fraction from 67 centers in the United States, Europe and Israel. 

Patients were randomized to receive one dose of either gene therapy (n=121) or placebo (n=122) and then followed for at least one year.

The primary efficacy endpoint was time to recurrent events, defined as hospitalizations or ambulatory treatment for worsening heart failure. The secondary efficacy endpoint was time to first terminal event, defined as all-cause death, heart transplant or implantation of a mechanical circulatory support device (MCSD). 

After a median follow-up period of 17.5 months, patients in the gene therapy group did not show improvements in either the primary or secondary endpoints compared to the placebo group.

Specifically, there were 104 recurrent events and 36 terminal events in the gene therapy arm compared to 128 and 29, respectively, in the placebo arm (hazard ratio [HR] 0•93, P=0•81 and HR 1•27, p=0•40 respectively). No safety issues were noted.

“Why infusion of SERCA2a did not improve outcomes in CUPID 2 is not certain and review of the data is underway to try to understand this,” said Greenberg.

“Although preliminary results in experimental models and in pilot studies of heart failure patients showed favorable results, it is possible that SERCA2a may not be an appropriate target for treating heart failure in human patients, and that the positive pilot study results could just be a chance finding.”

“Although deficiencies in SERCA2a activity and their correction by gene transfer have been demonstrated in animals, it is possible that these findings are not applicable in human heart failure and that raising the level of SERCA2a activity cannot alter the trajectory of the disease,” he suggested.

“Although CUPID 2 did not meet its end-points, it was an important study and the results should help inform future efforts using gene therapy to treat heart failure.”

The study was funded by Celladon Corp. Greenberg has been a consultant for and received honoraria from Celladon.

For more information:

Related Content

New Target for Treating Heart Failure Identified by Penn Medicine Researchers

Microtubules in heart cells from a healthy patient (left) and from a patient with heart failure. The dense network of detyrosinated microtubules impedes the motion of the failing heart cell during the heart beat. Credit: Ben Prosser lab, Perelman School of Medicine, University of Pennsylvania

News | Heart Failure | June 25, 2018
New research finds changes in cellular struts called microtubules (MT) can affect the stiffness of diseased human heart...
Gencaro Does Not Reduce Atrial Fibrillation Risk in Heart Failure Patients
News | Heart Failure | May 30, 2018
Data from the GENETIC-AF trial was presented in a “Late Breaking Clinical Trials” oral presentation at the European...
Cardiac Contractility Modulation Safe and Effective as Heart Failure Treatment

Image courtesy of Impulse Dynamics

News | Heart Failure | May 18, 2018
In a new study, cardiac contractility modulation (CCM) therapy was confirmed to significantly improve exercise...
V-Wave Closes $70M Financing to Support Pivotal Study of Heart Failure Therapy
News | Heart Failure | May 16, 2018
Israel-based V-Wave Ltd. recently closed a $70 million Series C financing for its proprietary, minimally invasive...
News | Heart Failure | May 14, 2018
Ancora Heart Inc. announced the expansion of the company’s U.S. feasibility study to evaluate the investigational...
Protein Clumping May Contribute to Heart Failure Development

A PET scan detects clumping proteins in rat hearts (top). The enlarged heart (right) is one with heart failure. Other PET scans showing blood flow in the rat hearts (bottom) show that the protein clumps aren't due to circulation problems. Image courtesy of Circulation Research, May 11, 2018.

News | Heart Failure | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
Minnesota Living With Heart Failure Questionnaire Qualified for FDA Medical Device Development Tools Program

The CORolla device from Israel-based CorAssist is one example of new devices being manufactured and tested to treat heart failure. The efficacy of this and other new devices under development can now be assessed with the Minnesota Living With Heart Failure Questionnaire. 

Technology | Heart Failure | May 07, 2018
The U.S. Food and Drug Administration (FDA) has qualified the Minnesota Living with Heart Failure Questionnaire from...
Nation's First Heart Failure and Arrhythmia Center Opening in Ohio

Image courtesy of The Ohio State University

News | Heart Failure | April 04, 2018
The Ohio State University Wexner Medical Center will establish the nation’s first center dedicated to treating those...
Abbott Initiates GUIDE-HF Trial for Improved Outcomes With CardioMEMS Monitor
News | Heart Failure | March 29, 2018
Abbott announced the company has initiated the landmark GUIDE-HF clinical trial using the CardioMEMS HF System. The...
Overlay Init